GlassScriptPhysician profile
Sundee Naing
NPI 1720010408
$6,064.70
in general payments reported to CMS, 2019-2025
32 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $896 · 2020: $623 · 2021: $1,189 · 2022: $998 · 2023: $446 · 2024: $806 · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,358.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,358.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $983.48 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Pfizer INC. | $594.71 | 2019-2025 | |
| Abbvie INC. | $583.83 | 2019-2025 | |
| Amgen INC. | $527.67 | 2019-2022 | |
| Lilly USA, LLC | $512.53 | 2020-2024 | Mounjaro, Trulicity, Zepbound |
| Novo Nordisk INC | $474.50 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Merck Sharp & Dohme LLC | $327.31 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $264.24 | 2020-2023 | Spravato |
| Intra-Sana Laboratories | $234.60 | 2025 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Allergan, INC. | $207.24 | 2019-2020 | |
| Exact Sciences Corporation | $194.48 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.00 | 2025 | Jardiance |
| Teva Pharmaceuticals USA, INC. | $124.91 | 2020 | |
| Neurocrine Biosciences, INC. | $124.77 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.59 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $100.97 | 2020-2021 | |
| Glaxosmithkline, LLC. | $97.60 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $88.08 | 2022 | |
| Amarin Pharma, INC. | $54.11 | 2020-2021 | |
| Madrigal Pharmaceuticals | $48.14 | 2025 | Rezdiffra |
| Shionogi INC | $37.72 | 2024 | Fetroja |
| Philips North America LLC | $36.76 | 2025 | Vest Therapy Und |
| Novartis Pharmaceuticals Corporation | $30.04 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.60 | 2024 | Aralast |
| Aytu Biopharma, INC. | $22.39 | 2019 | |
| Shield Therapeutics INC | $22.19 | 2024 | |
| Actelion Pharmaceuticals US, INC. | $21.58 | 2024 | Opsumit |
| Biogen, INC. | $19.77 | 2021 | |
| Shire North American Group INC | $18.20 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.63 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $14.62 | 2019 | |
| Eisai INC. | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sundee Naing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.